Is femtosecond LASIK the best option?

Article

A comparative analysis between manual and automated surgery

Initially, flap creation was performed by means of mechanical microkeratomes, with the inconvenience of the generation of flaps that were thinner in the centre than in the periphery, (meniscus-shaped configuration).2 This meniscus of tissue behaved as an additional optical element of the ocular system, inducing new higher order aberrations and modifying the predictability of the second order correction.3

Improvements in mechanical microkeratomes aimed at providing flaps with a more homogeneous thickness profile (planar flap configuration) and of less thickness to leave a thicker stromal residual bed have been developed and introduced in the clinical setting in the last few years. Likewise, femtosecond lasers for LASIK have been also introduced, which are now considered as a significant advancement for corneal laser refractive surgery.4 This type of photodisruptive laser that uses an infrared Nd:Glass laser beam (wavelength 1053 nm) allows the surgeon to program flap creation at a predetermined depth with a high degree of precision.

Our clinical experience

The clinical histories of all patients that had undergone LASIK surgery in our centre since May 2000 were retrospectively reviewed. A total of 13000 surgical procedures had been performed with the mechanical microkeratome Hansatome (Bausch + Lomb, Rochester, New York, USA) and 2000 procedures with the Amadeus microkeratome (Ziemer Ophthalmic Systems, Port, Switzerland). A total of 800 LASIK procedures had been performed with the IntraLase iFS femtosecond technology (Abbott Medical Optics, Santa Ana, California, USA) since January 2011.

According to the clinical guidelines of our centre, a complete preoperative ophthalmological examination had been performed in all cases to evaluate the viability of the corneal surgical procedure. It included uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA), manifest refraction, slit-lamp biomicroscopy, Goldman tonometry, scotopic pupil size measurement, corneal topography, ultrasound pachymetry, biometry, ocular wavefront aberrometry and funduscopy.

The following conditions were considered as exclusion criteria for surgery: estimated stromal residual bed thickness below 250 μm after programming the laser ablation, significant corneal topographic asymmetry, cataract, glaucoma, previous ocular surgery, keratoconus, and any active ocular disease. We only considered for the analysis those cases in which the target postoperative refraction had been emmetropia.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.